- Natco Pharma reported a 60.8% YoY decline in Q2FY27 net profit to Rs 203 crore
- Revenue from operations fell 29% YoY to Rs 967 crore in Q2FY27 from Rs 1,363 crore
- EBITDA dropped 55.4% to Rs 258.3 crore in Q2FY27 from Rs 579 crore a year ago
Natco Pharma Ltd. reported a 60.8% year-on-year (YoY) decline in net profit to Rs 203 crore in the September quarter of financial year 2027 (Q2FY27), compared with Rs 518 crore in the corresponding quarter last year (Q2FY26).
Revenue from operations or top line declined 29% YoY to Rs 967 crore in Q2FY27, from Rs 1,363 crore in the year-ago period.
At the operating level, earnings before interest, taxes, depreciation and amortisation (EBITDA) fell 55.4% to Rs 258.3 crore, compared with Rs 579 crore a year ago.
Subsequently, the pharma major's EBITDA margin squeezed 1,580 basis points (bps) to 26.7% in the quarter under review from 42.5% in the corresponding quarter last year, marking a decline of 1,580 basis points.
Other income also declined to Rs 52 crore from Rs 100 crore in the year-ago period.
After the results, Natco Pharma shares came under pressure, falling as much as 3.60% to an intraday low of Rs 779.65. The stock recovered from its day's lows but continued to trade in the red. At 2:21 pm, Natco Pharma shares were down 1.70% at Rs 795.05.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.